Semax: what the research actually shows
Semax has more human data than most peptides on this list. It has far less than FDA approval would require.
Why I looked into this
Semax is the peptide in this cohort with the most interesting regulatory arc. It has been approved and clinically used in Russia for years, primarily for ischemic stroke, with a parallel nootropic reputation. In the US it lives in gray-market nootropic communities with claims ranging from focus to ADHD to anxiety.
I wanted to separate the Russian clinical record from the Western reputation, and both of those from the gray-market sales pitch. All three are different things.
What Semax actually is
Semax is a synthetic heptapeptide, an analog of the amino-acid sequence 4 to 7 of adrenocorticotropic hormone (ACTH), extended with proline-glycine-proline. It was developed at the Institute of Molecular Genetics in Russia and approved there for ischemic stroke and other neurological indications.
Semax does not have ACTH’s corticosteroid-releasing activity. Its proposed mechanism involves BDNF and NGF upregulation in the brain, along with modulation of dopaminergic and serotonergic signaling. It is administered intranasally in standard clinical use.
What the human research shows
Do published human studies exist?
Yes, primarily in Russian-language clinical trials. Several studies tagged as “Clinical Trial” on PubMed report ischemic stroke outcomes with Semax intranasal administration. Most are Russian-language with English abstracts only. Western-standard double-blind placebo-controlled RCTs published in major English-language journals are not part of the record.
What do those studies report?
- Gusev et al. 2018, Zh Nevrol Psikhiatr Im S S Korsakova. n=110 post-stroke patients in early and late rehabilitation with or without intranasal Semax. Reported increased plasma BDNF, improved Barthel index, faster motor recovery. Russian-language with English abstract.
- Panikratova et al. 2020, Dokl Biol Sci. Functional MRI study in healthy volunteers comparing Semax and Selank effects on resting-state networks. Small imaging study.
- Vanhee et al. 2020, Drug Test Anal. Analysis of seized “research peptide” preparations sold as Semax and Selank. Documents purity and identity problems in gray-market supply.
- Earlier Russian clinical work by the Skvortsova and Myasoedov groups from the 1990s and early 2000s supported Semax approval in Russia for stroke. Most are not indexed in PubMed or only indexed as Russian-language abstracts.
What the research does not show in humans
- No Western regulatory approval for any indication
- No high-quality double-blind placebo-controlled Western RCTs in indexed journals
- No human RCT evidence for ADHD, anxiety, depression, or “cognitive enhancement” in healthy adults
- No human trigeminal neuralgia data in Western literature beyond Russian clinical-practice reports
- No long-term Western safety data
- No pharmacokinetic data adequate by FDA approval standards
Known safety signals in humans
Russian clinical use spans decades and reports generally describe good tolerability at standard intranasal dosing. No clear serious adverse-event signal has emerged in the published record, but that record is limited.
A separate and important safety concern is supply-side: the Vanhee 2020 paper documented significant impurity and mis-identification problems in gray-market Semax samples. That is a supply issue, not a peptide issue, but it is what most US users encounter.
FDA and legal status in the US
The July 24 PCAC review will consider Semax for cerebral ischemia and trigeminal neuralgia. The committee can vote either way.
How to evaluate a source: the safety framework
I do not name vendors. I do not link to sellers. The goal is harm reduction, not facilitation.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable address
- Mass-spec identity verification against a reference standard
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- Vague or absent purity percentages
- Sells Category 2 substances for human use
The wrinkle for Semax specifically
The Vanhee 2020 analysis is worth re-stating here. Gray-market Semax samples have documented identity and purity problems. The peptide you think you are buying is not always the peptide you are getting.
Cost reality
Intranasal Semax in Russian clinical use is a manufactured pharmaceutical with documented quality standards. Gray-market research chemicals are a different product sold under the same name. Price alone will not tell you which is which.
Questions worth asking any source
Is the pharmacy 503A-licensed? Can they provide a COA? What is the identity-verification method? Where is the physical facility? A source that cannot answer has answered.
My honest take
Opinion, not evidence
This section is opinion. I have not used Semax. Everything above this line is sourced from the published record. Everything below is my personal perspective.
Semax is genuinely interesting because it has a real clinical use case outside the US. That is a different situation than peptides with zero human evidence, and I want to flag it honestly.
What would change the picture is a proper Western Phase 2 trial, ideally for the ischemic-stroke rehabilitation use case, ideally blinded and multi-center. The Russian trials are suggestive. They are not definitive by the standards the FDA applies.
The gray-market nootropic reputation is a completely separate thing, and it does not have a published trial record at all. If you are buying Semax for focus or ADHD, you are buying a hypothesis, not a tested indication.
I have not used Semax. If I had a stroke and my rehab team raised it as part of a recovery plan in a regulated setting, I would listen carefully. For everyday cognitive optimization, I am not interested. The evidence base for that use does not exist.
Questions to ask your doctor
If you are considering Semax for a neurological condition or for cognition, these are the questions I would bring.
- Given that the published human trials of Semax are mostly Russian-language and pre-date Western approval standards, what is your view on the evidence base?
- If I am looking at this for a specific condition (stroke recovery, neuralgia, cognitive complaints), what are the approved options we should exhaust first?
- How would you verify the identity and purity of any Semax I had access to?
- What would you want to monitor if I decided to proceed anyway?
- Are there interactions with medications I am currently taking that concern you?
- What evidence would you want to see before revisiting this conversation in six months?
What to do next
Read the FDA review article
The July 24 PCAC meeting will frame what access to Semax looks like going forward.
Open the FDA article →Download the visit-prep packet
Bring the evidence summary and the six questions into a real conversation with a neurologist or primary-care physician.
Get the packet →Work through the 503A checklist
Evergreen source-safety checklist for any peptide source.
Open the checklist →Sources
- Gusev et al. 2018, Zh Nevrol Psikhiatr 118(3.2):61-68. n=110 post-stroke rehabilitation study with Semax. Russian-language.
- Panikratova et al. 2020, Dokl Biol Sci 490(1):9-11. fMRI study comparing Semax and Selank in healthy volunteers.
- Vanhee et al. 2020, Drug Test Anal 12(3):371-381. Seized “research peptide” Semax and Selank samples, identity and purity issues documented.
- FDA, Category 2 interim list of bulk drug substances.
- Federal Register, April 16, 2026. PCAC meeting notice, docket FDA-2025-N-6895.
- WADA Prohibited List 2026, S0 category.
Semax was developed at the Institute of Molecular Genetics in Russia and is approved there for ischemic stroke. US regulatory status is unchanged by that approval.
Related monographs
TB-500
Small Phase 2 RCTs for dry eye and ulcers. No Phase 3, no muscle-injury evidence.
BPC-157
Under review July 23 for ulcerative colitis. Zero RCTs in humans.
FDA review July 2026
Seven peptides, two days. What the meeting means and what it does not.